After osimertinib, can we target resistance rather than move straight to chemo? SAFFRON: osimertinib + savolitinib vs platinum–pemetrexed in EGFRm/MET-OE/AMP NSCLC. PFS/OS toplines are positive; magnitude + safety await LBA6. Prof. Shun Lu @myESMO @IASLC #ESMO26 #LCSM https://t.co/Zyt7CbatSz